Wolf-Schnurrbusch, Ute; Zinkernagel, Martin; Munk, Marion R; Ebneter, Andreas; Wolf, Sebastian (2015). Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids. Investigative ophthalmology & visual science, 56(13), pp. 8069-8074. Association for Research in Vision and Ophthalmology 10.1167/iovs.15-17586
Text
i1552-5783-56-13-8069.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (657kB) |
Purpose
It has been shown that lutein and zeaxanthin accumulate in the macula where they enhance contrast sensitivity and may reduce the risk of progression to advanced age-related macular degeneration (AMD). Furthermore, omega-3 long-chain polyunsaturated fatty acids (PUFA) might further reduce this risk. However, controversy exists regarding whether PUFA may reduce the bioavailability of lutein.
Methods
This was a prospective 12-month, randomized, open label study evaluating the effect of supplementation with lutein, other antioxidants, and minerals on contrast sensitivity (CS) and macular pigment optical density (MPOD) in patients with age-related maculopathy. A total of 79 patients were randomized to either lutein (10 mg) and antioxidant supplement or lutein and antioxidant supplement in combination with PUFA. Patients received supplementation for a period of 6 months and were followed for a total of 12 months.
Results
Serum lutein and zeaxanthin increased significantly by the first follow-up visit at 1 month, and remained elevated throughout the intervention period of 6 months in the lutein-only group but not in the lutein+PUFA group. Macular pigment optical density and CS increased significantly in the lutein-only group (P < 0.005) but not in the lutein+PUFA group (P = 0.059) compared to baseline. Best-corrected visual acuity remained unchanged during the entire study period in both groups.
Conclusions
Addition of PUFA may reduce the bioavailability of lutein and therefore lessen the beneficial effect on macular pigment and CS. This needs to be considered when prescribing lutein supplements to patients with low lutein levels. (ClinicalTrials.gov number, NCT00563979.).
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology |
UniBE Contributor: |
Wolf-Schnurrbusch, Ute, Zinkernagel, Martin Sebastian, Ebneter, Andreas, Wolf, Sebastian (B) |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0146-0404 |
Publisher: |
Association for Research in Vision and Ophthalmology |
Language: |
English |
Submitter: |
Sebastian Wolf |
Date Deposited: |
12 Jan 2016 16:11 |
Last Modified: |
02 Mar 2023 23:27 |
Publisher DOI: |
10.1167/iovs.15-17586 |
PubMed ID: |
26720458 |
BORIS DOI: |
10.7892/boris.74541 |
URI: |
https://boris.unibe.ch/id/eprint/74541 |